Regulus Therapeutics (RGLS) Misses Q3 EPS by 2c

Regulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.18), $0.02 worse than the analyst estimate of ($0.16).

As of September 30, 2017, Regulus had cash, cash equivalents and short-term investments of $71.4 million.

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• After-Hours Stock Movers: FDX, CBRS, NKE